How effective is venetoclax in the treatment of chronic lymphocytic leukemia (CLL)?

Venetoclax is a BCL-2 inhibitor used to treat chronic lymphocytic leukemia, small lymphocytic lymphoma, or acute myeloid leukemia (AML). Veneclaris used to treat adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). VeneclatIn combination with azacitidine, decitabine, or low-dose cytarabineAdults 75 years or older with newly diagnosed acute myeloid leukemia (AML) or with comorbidities that preclude the use of intensive induction chemotherapy.

How effective is venetoclax in the treatment of chronic lymphocytic leukemia(CLL)?

In a comparisonvenetoclaxplusObinutuzumab (V+O) vs.ObinutuzumabIn trials plus chlorambucil (O+C), on average2 8months later (ranging from 0 to 36months), V+O 13% of the group experienced an incident, while 37% experienced it, compared with 33%of theO+C group span>V+O6% had disease progression and 6%of the V+O group had disease progression 7% died, while only 4% died in the O+C group, and only 4% died in the V+O group The overall response rate was 85%, while the O+C group was 71%

Forty-six percent of patients in the V+O group experienced complete remission, compared with 22% of patients in the O+C group. The Murano trial compared venetoclax plus rituximab (VEN+R) with bendamustine plus rituximab (B+R) with a median follow-up of B+R pan>23.4months:Ven +13%of the R group experienced disease progression, VEN + There were 9 deaths in the R group (out of 194 persons), and 15 deaths in the B+R group, VEN + The overall response rate was 92% in the R group and 72% in the B+R group. When venetoclax was used as the sole therapy, trials reported overall response rates of 70% to 80%, with about 6% experiencing a complete response. The retail price of generic venetoclax100mg120 tablets ranges from 2 to 6 more than a thousand. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.